Information and analytics group RELX PLC (LSE:REL) is "an AI winner with catalysts", according to UBS, that most of its business segments stand to gain from artificial intelligence, rather than be disrupted by it.
A ‘buy’ rating was reiterated by analysts at the Swiss bank, along with a 12-month price target of 4,570p, implying 32% upside from Friday’s close at 3,459p.
The analysts calculated that around 88% of the FTSE 100 group's revenue comes from "sub-segments where we see very little risk of any AI disruption".
Divisions such as Risk and Legal should benefit from growing demand for fraud protection and AI-powered legal tools, they added, while its Exhibitions division is also seen as low risk.
The academic publishing business within Scientific, Technical & Medical (STM) is believed to be at low risk of AI disruption.
Within the STM segment there are a range of tools and databases that make up around 12% of group revenue, with AI versions of many of these products already launched, such as Clinical Key AI.
"We do acknowledge, however, that with more academic content than ever available outside of paywalls, there is an opportunity for new entrants to build competing products and this may stoke investor debate as to whether high-single-digit growth is sustainable.
"In our view, most of RELX's products here should benefit from their exclusive access to new content published by Elsevier journals, as well as their proprietary citation data."
Analysts expect upcoming investor events and potential share buybacks to act as catalysts, forecasting an acceleration in group underlying revenue growth to 8% in the first half of 2026.